-
1 Comment
Guangdong VTR Bio-Tech Co., Ltd is currently in a long term downtrend where the price is trading 14.2% below its 200 day moving average.
From a valuation standpoint, the stock is 79.2% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2.0.
Guangdong VTR Bio-Tech Co., Ltd's total revenue sank by 20.5% to $513M since the same quarter in the previous year.
Its net income has increased by 20.9% to $54M since the same quarter in the previous year.
Finally, its free cash flow grew by 69.7% to $91M since the same quarter in the previous year.
Based on the above factors, Guangdong VTR Bio-Tech Co., Ltd gets an overall score of 3/5.
| Sector | Healthcare |
|---|---|
| Industry | Biotechnology |
| ISIN | CNE100001RJ8 |
| Exchange | SHE |
| CurrencyCode | CNY |
| Target Price | None |
|---|---|
| Dividend Yield | 0.8% |
| Market Cap | 4B |
| PE Ratio | 249.67 |
| Beta | 0.41 |
Guangdong VTR Bio-Tech Co., Ltd. researches, develops, produces, sells, and services biological enzyme preparations, biosynthetics, and nutrition and health products in China. The company offers feed, energy, washing, food, papermaking, and textile enzymes, as well as biotechnology solutions. It also provides active natural products. The company also exports its products. The company was founded in 1991 and is headquartered in Zhuhai, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 300381.SHE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
